Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing library of Dark Antigens that can address the need for novel, cancer-specific targets in solid tumors. Our internal focus is developing TCR-directed immunotherapies against Dark Antigen targets that are highly prevalent and homogenously expressed across solid tumors. Our partner, Boehringer Ingelheim, is combining multiple Dark Antigens to create off-the-shelf therapeutic cancer vaccines. Based in Oxford, UK, Enara Bio is backed by a strong syndicate of life science investors including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. For more information, visit: www.enarabio.com.
Comments and DMs to this account are not monitored, for any further information please head to our website
Company Details
- Employees
- 61
- Address
- Magdalen Centre, The Oxford Science Park, 1 Robert Robinson Avenue,united Kingdom
- Industry
- Biotechnology
- Website
- ervaxx.com
- Keywords
- Oxford.
- HQ
- Oxford, Oxfordshire
Enara Bio Questions
Enara Bio's website is ervaxx.com
Enara Bio's LinkedIn profile is https://uk.linkedin.com/company/enarabio
Enara Bio has
61 employees.
View email and phone details for 61
employees at Enara Bio.
Enara Bio's industry is
Biotechnology
Enara Bio's top competitors are
Evox Therapeutics Ltd,
Adaptimmune,
Constructive Bio,
Kailera Therapeutics,
Triveni Bio,
Immunocore,
Resolution Therapeutics,
Nucleome Therapeutics,
Loqus23 Therapeutics Ltd,
T-Cypher Bio.
Enara Bio's categories are Biotechnology
